Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy

Recruiting

Phase 2

TopotecanIntravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy

Sponsor:

Unity Health Toronto

Code:

NCT05523869

Conditions

Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Intravitreal topotecan

Pars plana vitrectomy with or without scleral buckle

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-05. This information was provided to ClinicalTrials.gov by Unity Health Toronto on 2025-02-11.